Propanc Biopharma Inc (PPCB)

[swamp-rat]

Recent News Headlines for Propanc Biopharma Inc
Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP
Thursday 04/27/2017 08:51 AM ET - MarketWire via Dow Jones News
Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP Safe Starting Dose for First-In-Human Studies Defined, Clinical Development Stage Commences MELBOURNE, AUSTRALIA--(Marketwired - April 27, 2017) - Propanc Biopharma, Inc. (OTCQB: PPCH) (OTCQB: PPCHD) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the successful completion of the GLP-compliant, 28-day repeat-dose toxicity study for its lead product, PRP. Importantly, there were no major toxicological findings after administration of PRP by intravenous injection once daily throughout the study period. PRP is a combination of pancreatic proenzymes trypsinogen and chymotrypsinogen in solution, for once daily intravenous administration.